866-997-4948(US-Canada Toll Free)

Ramucirumab (Gastric Cancer) - Analysis and Forecast to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Cancer

No. of Pages : 29 Pages


GlobalDatas pharmaceuticals report, Ramucirumab (Gastric Cancer) - Analysis and Forecast to 2020 provides Ramucirumab sales forecasts for US, and EU-5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2020). The report also includes information on Oncology's Disease market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope
  • Therapy area profile including patient population for the US and EU5 (seven major markets)
  • Analysis and review of Ramucirumab including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Ramucirumab including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2014-2020 for Ramucirumab in in each of the US and EU5 markets

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Contents 

1 Table of contents 2
1.1 List of Tables 2
1.2 List of Figures 3

2 Introduction 4
2.1 Gastric Cancer Market 4
2.2 Gastric Cancer Disease 4
2.3 GlobalData Pipeline Report Guidance 7

3 Baldder Cancer Disease: Market Characterization 7
3.2 Gastric Cancer Disease Market 7
3.3 Gastric Cancer Disease Market Forecasts and CAGR 7
3.4 Drivers for the Gastric Cancer Disease Market 8
3.4.1 High Prevalence 8
3.4.2 High Incidence 9
3.4.3 Low Initial Diagnosis Rate 10
3.4.4 High Mortality Rate 10

4 Tumor Node Metastases(TNM) Classification of Gastric Cancer 10

5 Ramucirumab 14

6.1 Introduction 14

6.2 Mechanism of Action 14
6.3 Clinical Studies 14
6.4 Approval History of Ramucirumab 15
6.5 Factors Impacting Sales of Ramucirumab 16
6.5.1 Gastric Cancer Market 16
6.5.2 Average Efficacy 16
6.5.3 Beneficial for Refractory or Platinum and FluoropyrimidineTherapy Failed Patients 16
6.5.4 Lower in Price Compared to Competitor 16
6.5.5 High Competition 16
6.6 Drug Evaluation 16
6.6.1 Efficacy 17
6.6.2 Safety 17
6.6.3 Compliance 17
6.6.4 Dosing Convenience 17
6.6.5 Competition 17
6.7 Sales forecast 18
6.7.1 Target Patient Pool of Ramucirumab 18
6.7.2 Dosing 19
6.7.3 Market Penetration 19
6.7.4 Annual Cost of Therapy 19
6.7.5 Sales Projections of Ramucirumab 20

7 Gastric Cancer Market: Appendix 27
7.1 Market Definitions 27
7.2 List of Abberiviations 27
7.3 Research Methodology 27
7.3.1 Coverage 27
7.3.2 Secondary Research 27
7.3.3 Forecasting 28
7.3.4 Number of Patients Approved to take the Drug 28
7.3.5 Net Penetration of Drug 28
7.3.6 Net Annual Dosing 28
7.3.7 Annual Cost of Therapy 29
7.3.8 Primary Research 29
7.3.9 Expert Panels 29
7.4 Contact Us 29
7.5 Disclaimer 29
7.6 Sources 29

List of Table


Table 1: Gastric Cancer Incidences and Mortality, 2008-2030 4
Table 2: Gastric Cancer, Global, Market Forecast ($bn), 20092020 7
Table 3: Approval History of Ramucirumab 14
Table 4: Drug Risk Benefit Score of Ramucirumab 16
Table 5: Annual Cost of Therapy of Ramucirumab 18
Table 6: Gastric Cancer, Global, Sales Forecast of Ramucirumab ($m) 2014-2020 19
Table 7: Gastric Cancer, The US, Sales Forecast of Ramucirumab ($m) 2014-2020 21
Table 8: Gastric Cancer, The UK, Sales Forecast of Ramucirumab ($m) 2014-2020 22
Table 9: Gastric Cancer, France, Sales Forecast of Ramucirumab ($m) 2014-2020 23
Table 10: Gastric Cancer, Germany, Sales Forecast of Ramucirumab ($m) 2014-2020 24
Table 11: Gastric Cancer, Italy, Sales Forecast of Ramucirumab ($m) 2014-2020 25
Table 12: Gastric Cancer, Spain, Sales Forecast of Ramucirumab ($m) 2014-2020 26

List of Chart


Figure 1: Percentage Distribution of Top 20 Diagnosed Cancers 4
Figure 2: : Fatality = [(%Distribution of Incidence) (% Distribution Mortality )] of Top 20 Cancers 5
Figure 3: Smoking Consumption Curve, The US, 1960-2006 6
Figure 4: Gastric Cancer, Global, Forecasted Market, ($bn), 2009-2020 7
Figure 5: Oncology, Global, Incidence (in millions), 2008-2030 8
Figure 6: Gastric Cancer, Global, Incidence (in millions), 2008-2030 9
Figure 7: Broad Classification of Gastric Cancer in the US and EU-5 10
Figure 8: Broad Classification of Gastric Cancer in Japan 10
Figure 9: Detailed TNM Classification 11
Figure 10: Classification of Gastric Cancer in the US and EU-5 12
Figure 11: Classification of Gastric Cancer in Japan 12
Figure 12: Drug Model Diagram of Ramucirumab in the US and the EU-5 17
Figure 13: Gastric Cancer, Global, Sales Forecast of Ramucirumab ($m) 2014-2020 19
Figure 14: Gastric Cancer, the US and the EU, Ramucirumab Sales Distribution, 2014 19
Figure 15: Gastric Cancer, The US, Sales Forecast of Ramucirumab ($m) 2014-2020 21
Figure 16: Gastric Cancer, The UK, Sales Forecast of Ramucirumab ($m) 2014-2020 22
Figure 17: Gastric Cancer, France, Sales Forecast of Ramucirumab ($m) 2014-2020 23
Figure 18: Gastric Cancer, Germany, Sales Forecast of Ramucirumab ($m) 2014-2020 24
Figure 19: Gastric Cancer, Italy, Sales Forecast of Ramucirumab ($m) 2014-2020 25
Figure 20: Gastric Cancer, Spain, Sales Forecast of Ramucirumab ($m) 2014-2020 26

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *